Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPNE1 small interfering RNA lentiviral vector
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
CPNE1 small interfering RNA lentiviral vector is a gene therapy research tool designed to silence the expression of the CPNE1 (Copine 1) gene. It utilizes a lentiviral vector system, often based on the pGCSIL-GFP plasmid, to deliver a specific small interfering RNA (siRNA) sequence (e.g., 5′-CACACAACTGGTCTCATACTT-3′) into target cells. CPNE1 is a calcium-dependent phospholipid-binding protein that has been identified as an oncogene in various cancers, including osteosarcoma and non-small cell lung cancer (NSCLC). By knocking down CPNE1 expression, this tool inhibits cell proliferation, migration, and invasion, and can enhance sensitivity to chemotherapeutic agents like cisplatin and adriamycin. It is primarily used in preclinical academic research to study tumorigenesis and evaluate CPNE1 as a potential therapeutic target.
- Other names
- CPNE1 siRNA lentiviral vectorCPNE-1 siRNA lentiviral vectorCPNE 1 siRNA lentiviral vectorpGCSIL-GFP-CPNE1-siRNApGCSIL-GFP-CPNE-1-siRNApGCSIL-GFP-CPNE 1-siRNAlentiviral-mediated CPNE1 siRNA
02
Targets
CPNE1 (Copine 1)
Beyond the preview
Go deeper on CPNE1 small interfering RNA lentiviral vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPNE1 small interfering RNA lentiviral vector.